Subdivision of molecularly-classified groups by new gene signatures in breast cancer patients

Oncology Reports

Volumn 28, Issue 6, 2012, Pages 2255-2263

  Armakolas, Athanasios ^a   Stathopoulos, George P ^b,c   Nezos, Adrianos ^a   Theos, Apostolos ^a   Stathaki, Martha ^a   Koutsilieris, Michael ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b Errikos Dunant Hospital   (Greece)

^c NONE   (Greece)

Author keywords

Breast cancer; HER2 subtype patients; Real time RT PCR

Indexed keywords

EID: 84868221537     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.2018     Document Type: Conference Paper

References (37)

1. Sotiriou C and Pusztai L: Gene-expression signatures in breast cancer. N Engl J med 360:790-800, 2009.
2. Oakman C, Santarpia L and Di Leo A: Breast cancer assessment tools and optimizing adjuvant therapy. Nat Rev Clin Oncol 7:723-732, 2010.
3. Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-kains B, Desmedt C, Ignatiadis M, Sengstag T, Schütz F, et al: meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 10:R65, 2008.
4. Weigelt B, Hu Z, He X, Livasy C, Carey LA, Ewend MG, Glas AM, Perou CM and Van't Veer LJ: molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res 65:9155-9158, 2005. (Pubitemid 41507977)
5. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, et al: Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27:1160-1167, 2009.
6. Correa Geyer F and Reis-Filho JS: microarray-based gene expression profiling as a clinical tool for breast cancer management: are we there yet? Int J Surg Pathol 17:285-302, 2009.
7. Cosler LE and Lyman GH: Economic analysis of gene expression profile data to guide adjuvant treatment in women with earlystage breast cancer. Cancer Invest 27:953-959, 2009.
8. Perou CM, Sorlie T, Eisen MB, Van De Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al: molecular portraits of human breast tumours. Nature 406:747-752, 2000.
9. Feng Y, Li X, Sun B, Wang Y, Zhang L, Pan X, Chen X, Wang X, Wang J and Hao X: Evidence for a transcriptional signature of breast cancer. Breast Cancer Res Treat 122:65-75, 2009.
10. Creighton CJ, Fu X, Hennessy BT, Casa AJ, Zhang Y, Gonzalez-Angulo AM, Lluch A, Gray JW, Brown PH and Hilsenbeck S: Proteomic and transcriptomic profiling reveals a link between the PI3k pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer. Breast Cancer Res 12:R40, 2010.
11. Chernov AV, Baranovskaya S, Golubkov VS, Wakeman DR, Snyder EY, Williams R and Strongin AY: micro array-based transcriptional and epigenetic profiling of matrix metalloproteinases, collagens, and related genes in cancer. J Biol Chem 285:19647-19659, 2010.
12. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, et al: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100:8418-8423, 2003. (Pubitemid 36842560)
13. Miecznikowski JC, Wang D, Liu S, Sucheston L and Gold D: Comparative survival analysis of breast cancer microarray studies identifes important prognostic genetic pathways. BmC Cancer 10:573, 2010.
14. Chen H, Pimienta G, Gu Y, Sun X, Hu J, Kim MS, Chaerkady R, Gucek M, Cole RN, Sukumar S and Pandey A: Proteomic characterization of Her2/neu- overexpressing breast cancer cells. Proteomics 16:3600-3610, 2010.
15. Tebbit CL, Zhai J, Untch BR, Ellis MJ, Dressman HK, Bentley RC, Baker JA, Marcom PK, Nevins JR, Marks JR and Olson JA Jr: Novel tumor sampling strategies to enable microarray gene expression signatures in breast cancer: a study to determine feasibility and reproducibility in the context of clinical care. Breast Cancer Res Treat 118:635-643, 2009.
16. Centeno BA, Enkemann SA, Coppola D, Huntsman S, Bloom G and Yeatman TJ: Classification of human tumors using gene expression profiles obtained after microarray analysis of fineneedle aspiration biopsy samples. Cancer 105:101-109, 2005. (Pubitemid 40604944)
17. Stathopoulos GP and Armakolas A: differences in gene expression between individuals with multiple primary and single primary malignancies. Int J mol med 24:613-622, 2009.
18. Sørlie T: molecular classification of breast tumors: toward improved diagnostics and treatments. methods mol Biol 360:91-114, 2007.
19. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, Van De Rijn M, Jeffrey SS, et al: hnRNP C is required for postimplantation mouse development but Is dispensable for cell viability. mol Cell Biol 20:4094-4105, 2000.
20. Adachi Y, Pavlakis GN and Copeland TD: Identification and characterization of SET, a nuclear phosphoprotein encoded by the translocation break point in acute undifferentiated leukemia. J Biol Chem 269:2258-2262, 1994. (Pubitemid 24035441)
21. Canela N, Rodriguez-Vilarrupla A, Estanyol JM, Diaz C, Pujol MJ, Agell N and Bachs O: The SET protein regulates G2/m transition by modulating cyclin B-cyclin-dependent kinase 1 activity. J Biol Chem 278:1158-1164, 2003. (Pubitemid 36790797)
22. Ozbek U, Kandilci A, Van Baal S, et al: SET-CAN the product of t (9;9) in acute undifferentiated leukaemia, causes expansion of early haematopoietic progenitors and hyperproliferation of stomach mucosa in transgenic mice. Am J Pathol 171:654-666, 2007. (Pubitemid 47344697)
23. Ralph S, Brenchley PE, Summers A, Rosa DD, Swindell R and Jayson GC: Heparanase gene haplotype (CGC) is associated with stage of disease in patients with ovarian carcinoma. Cancer Sci 98:844-849, 2007. (Pubitemid 46691821)
24. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, Van De Rijn M, Jeffrey SS, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869-10874, 2001. (Pubitemid 32878711)
25. Lutz M, Wempe F, Bahr I, Zopf D and Von Melchner H: Proteasomal degradation of the multifunctional regulator YB-1 is mediated by an F-Box protein induced during programmed cell death. FEBS Lett 580:3921-3930, 2006. (Pubitemid 43946885)
26. Antonicka H, Ostergaard E, Sasarman F, Weraarpachai W, Wibrand F, Pedersen AM, Rodenburg RJ, Van Der Knaap MS, Smeitink JA, Chrzanowska- Lightowlerszm and Shoubridge EA: Mutations in C12orf65 in patients with encephalomyopathy and a mitochondrial translation defect. Am J Hum Genet 87:115-122, 2010.
27. Sowa ME, Bennett EJ, Gygi SP and Harper JW: defining the human deubiquitinating enzyme interaction landscape. Cell 138:389-403, 2009.
28. Torrini M, Marchese C, Vanzetti M, Marini V, Origone P, Garré C and Mareni C: mutation analysis of oxisterol-bindingprotein gene in patients with age-related macular degeneration. Genet Test 11:421-426, 2007.
29. Chen D, Zhang Z, Li M, Wang W, Li Y, Rayburn ER, Hill DL, Wang H and Zhang R: Ribosomal protein S7 as a novel modulator of p53-mdm2 interaction: binding to mdm2, stabilization of p53 protein, and activation of p53 function. Oncogene 26:5029-5037, 2007. (Pubitemid 47206956)
30. Costanzo M, Baryshnikova A, Bellay J, Kim Y, Spear ED, Sevier CS, Ding H, Koh JL, Toufighi K, Mostafavi S, et al: The genetic landscape of a cell. Science 22:327:425-431, 2010.
31. Doong H, Rizzo K, Fang S, Kulpa V, Weissman AM and Kohn EC: CAIR-1/BAG-3 abrogates heat shock protein-70 chaperone complex-mediated protein degradation: accumulation of poly-ubiquitinated Hsp90 client proteins. J Biol Chem 278:28490-28500, 2003. (Pubitemid 36935751)
32. Du X, Nagata S, Ise T, Stetler-Stevenson M and Pastan I: FCRL1 on chronic lymphocytic leukemia, hairy cell leukemia, and B-cell non-Hodgkin lymphoma as a target of immunotoxins. Blood 111:338-343, 2008.
33. Malek SN, Dordai DI, Reim J, et al: Malignant transformation of early lymphoid progenitors in mice expressing an activated Blk tyrosine kinase. Proc Natl Acad Sci USA 95:7351-7356, 1998. (Pubitemid 28293255)
34. Tschumper RC, Geyer SM, Campbell ME, et al: Immunoglobulin diversity gene usage predicts unfavorable outcome in a subset of chronic lymphocytic leukemia patients. J Clinc Invest 118:306-315, 2008.
35. Vitek L and Schwertner HA: The heme catabolic pathway and its protective effects on oxidative stress-mediated diseases. Adv Clin Chem 43:1-57, 2007. (Pubitemid 44960959)
36. Mani A and Gelmann EP: The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol 23:4776-4789, 2005. (Pubitemid 46224082)
37. Yanagisawa M, Huveldt D, Kreinest P, et al: p120 catenin isoform switch affects Rho activity, induces tumor cell invasion and predicts metastatic disease. J Biol Chem 283:18344-18354, 2008.